U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07408518) titled 'Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes' on Feb. 04.
Brief Summary: The study team is conducting a consumer-driven, decentralized clinical research study to assess the impact of the consumer-grade probiotic supplement, iVS-1, on adults with moderate to severe gastrointestinal discomfort. Bifidobacterium adolescentis iVS-1 was chosen for its association with gastrointestinal health benefits and its safety profile, having been self-affirmed as GRAS and lacking antibiotic resistance and virulence genes. The study aims to evaluate the probiotic's effects not only on gastrointestinal symptoms but also on se...